{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:51:39Z","timestamp":1790819499799,"version":"4.1.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Many pediatric patients with heterozygous familial hypercholesterolemia (HeFH) cannot reach recommended low-density lipoprotein cholesterol (LDL-C) concentrations on statins alone and require adjunct lipid-lowering therapy (LLT); the use of alirocumab in pediatric patients requires evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy of alirocumab in pediatric patients with inadequately controlled HeFH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a phase 3, randomized clinical trial conducted between May 2018 and August 2022 at 43 centers in 24 countries. Pediatric patients aged 8 to 17 years with HeFH, LDL-C 130 mg\/dL or greater, and receiving statins or other LLTs were included. Following consecutive enrollment into dosing cohorts, 25 of 99 patients screened for dosing every 2 weeks (Q2W) failed screening; 25 of 104 patients screened for dosing every 4 weeks (Q4W) failed screening. A total of 70 of 74 Q2W patients (95%) and 75 of 79 Q4W patients (95%) completed the double-blind period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized 2:1 to subcutaneous alirocumab or placebo and Q2W or Q4W. Dosage was based on weight (40 mg for Q2W or 150 mg for Q4W if &amp;amp;lt;50 kg; 75 mg for Q2W or 300 mg for Q4W if \u226550 kg) and adjusted at week 12 if LDL-C was 110 mg\/dL or greater at week 8. After the 24-week double-blind period, patients could receive alirocumab in an 80-week open-label period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was percent change in LDL-C from baseline to week 24 in each cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 153 patients randomized to receive alirocumab or placebo (mean [range] age, 12.9 [8-17] years; 87 [56.9%] female), alirocumab showed statistically significant reductions in LDL-C vs placebo in both cohorts at week 24. Least squares mean difference in percentage change from baseline was \u221243.3% (97.5% CI, \u221256.0 to \u221230.7; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) Q2W and \u221233.8% (97.5% CI, \u221246.4 to \u221221.2; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) Q4W. Hierarchical analysis of secondary efficacy end points demonstrated significant improvements in other lipid parameters at weeks 12 and 24 with alirocumab. Two patients receiving alirocumab Q4W experienced adverse events leading to discontinuation. No significant difference in adverse event incidence was observed between treatment groups. Open-label period findings were consistent with the double-blind period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings in this study indicate that alirocumab Q2W or Q4W significantly may be useful for reducing LDL-C and other lipid parameters and be well tolerated in pediatric patients with HeFH inadequately controlled with statins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03510884\">NCT03510884<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapediatrics.2023.6477","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T16:01:24Z","timestamp":1707148884000},"page":"283","source":"Crossref","is-referenced-by-count":38,"title":["Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia"],"prefix":"10.1001","volume":"178","author":[{"given":"Raul D.","family":"Santos","sequence":"first","affiliation":[{"name":"Lipid Clinic Heart Institute, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Amsterdam University Medical Center, Emma Children\u2019s Hospital, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Caprio","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche Scientifique, Inserm, l\u2019Institut du Thorax, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[{"name":"Internal Medicine and Medical Specialties, Universit\u00e0 degli Studi di Palermo, Palermo, Italy"},{"name":"Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Poulouin","sequence":"additional","affiliation":[{"name":"IT&M Stats, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Scemama","sequence":"additional","affiliation":[{"name":"Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Garon","sequence":"additional","affiliation":[{"name":"Sanofi, North York, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Daniels","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"poi230095r1","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects.","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"poi230095r2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/heartjnl-2015-308845","article-title":"Cardiovascular risk stratification in familial hypercholesterolaemia.","volume":"102","author":"Sharifi","year":"2016","journal-title":"Heart"},{"issue":"6","key":"poi230095r3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel.","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"poi230095r4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia.","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"poi230095r5","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 5","key":"poi230095r6","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.","volume":"128 Suppl 5","year":"2011","journal-title":"Pediatrics"},{"issue":"36","key":"poi230095r7","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"poi230095r8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jacl.2020.03.001","article-title":"PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study.","volume":"14","author":"Daniels","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"14","key":"poi230095r9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia.","volume":"383","author":"Santos","year":"2020","journal-title":"N Engl J Med"},{"issue":"43","key":"poi230095r10","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1093\/eurheartj\/ehv370","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"poi230095r11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jacl.2020.07.009","article-title":"Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.","volume":"14","author":"Roth","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"5","key":"poi230095r12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher.","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"poi230095r15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5001\/omj.2014.22","article-title":"Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab Population.","volume":"29","author":"Al-Rasadi","year":"2014","journal-title":"Oman Med J"},{"issue":"5","key":"poi230095r16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jacl.2022.07.004","article-title":"Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: a systematic review.","volume":"16","author":"Masson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"poi230095r17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jpeds.2020.09.042","article-title":"Children with heterozygous familial hypercholesterolemia in the United States: data from the Cascade Screening for Awareness and Detection-FH Registry.","volume":"229","author":"de Ferranti","year":"2021","journal-title":"J Pediatr"},{"key":"poi230095r18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","article-title":"Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.","volume":"292","author":"Ramaswami","year":"2020","journal-title":"Atherosclerosis"},{"issue":"2","key":"poi230095r19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jacl.2017.11.009","article-title":"Treatment goal attainment in children with familial hypercholesterolemia: a cohort study of 302 children in Norway.","volume":"12","author":"Bogsrud","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9","key":"poi230095r20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/eurjpc\/zwac025","article-title":"Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.","volume":"29","author":"Reijman","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"poi230095r21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia.","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"9965","key":"poi230095r22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"poi230095r23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S2213-8587(22)00221-2","article-title":"Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT.","volume":"10","author":"Santos","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"poi230095r24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/pharmtox.2017.57.issue-1","article-title":"PCSK9: regulation and target for drug development for dyslipidemia.","volume":"57","author":"Burke","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"poi230095r25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"poi230095r26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk.","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"poi230095r28","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"poi230095r13","unstructured":"Regeneron. Praluent (alirocumab) injection (prescribing information). Accessed July 25, 2023. https:\/\/www.regeneron.com\/downloads\/praluent_pi.pdf"},{"key":"poi230095r14","unstructured":"Sanofi. Praluent, SmPC. Accessed July 25, 2023. https:\/\/products.sanofi.us\/praluent\/praluent.pdf"},{"key":"poi230095r27","unstructured":"Novartis Pharmaceuticals. Study to evaluate efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolemia (ORION-16). Updated November 27, 2023. Accessed December 21, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04652726"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2814614\/jamapediatrics_santos_2024_oi_230095_1708531145.6393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T16:01:29Z","timestamp":1709568089000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2814614"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2023.6477","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}